Seres Therapeutics’ (MCRB) Buy Rating Reaffirmed at Cowen

Cowen reiterated their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a research note issued to investors on Friday.

A number of other research firms have also issued reports on MCRB. Oppenheimer set a $16.00 target price on Seres Therapeutics and gave the company a buy rating in a report on Friday, November 9th. Cantor Fitzgerald set a $15.00 target price on Seres Therapeutics and gave the company a buy rating in a report on Thursday, November 8th. BidaskClub upgraded Seres Therapeutics from a sell rating to a hold rating in a report on Saturday, November 10th. Zacks Investment Research lowered Seres Therapeutics from a buy rating to a hold rating in a report on Wednesday, November 14th. Finally, ValuEngine upgraded Seres Therapeutics from a hold rating to a buy rating in a report on Tuesday, November 6th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $13.06.

NASDAQ:MCRB opened at $5.98 on Friday. The firm has a market capitalization of $244.75 million, a P/E ratio of -2.71 and a beta of 1.84. Seres Therapeutics has a 12-month low of $4.42 and a 12-month high of $10.32.



In other Seres Therapeutics news, insider Eric D. Shaff sold 4,378 shares of Seres Therapeutics stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $5.75, for a total transaction of $25,173.50. Following the completion of the sale, the insider now directly owns 17,220 shares of the company’s stock, valued at approximately $99,015. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Thomas Desrosier sold 5,471 shares of Seres Therapeutics stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $5.75, for a total value of $31,458.25. Following the sale, the executive vice president now directly owns 21,525 shares of the company’s stock, valued at $123,768.75. The disclosure for this sale can be found here. Insiders have sold a total of 24,131 shares of company stock valued at $147,894 over the last ninety days. 37.10% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC lifted its holdings in Seres Therapeutics by 0.4% during the 3rd quarter. FMR LLC now owns 6,119,349 shares of the biotechnology company’s stock worth $46,446,000 after buying an additional 23,749 shares during the last quarter. ARK Investment Management LLC lifted its holdings in Seres Therapeutics by 23.7% during the 3rd quarter. ARK Investment Management LLC now owns 4,040,735 shares of the biotechnology company’s stock worth $30,669,000 after buying an additional 774,307 shares during the last quarter. BlackRock Inc. lifted its holdings in Seres Therapeutics by 1.8% during the 3rd quarter. BlackRock Inc. now owns 2,281,563 shares of the biotechnology company’s stock worth $17,318,000 after buying an additional 40,719 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Seres Therapeutics by 3.4% during the third quarter. Renaissance Technologies LLC now owns 756,608 shares of the biotechnology company’s stock worth $5,743,000 after purchasing an additional 24,708 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Seres Therapeutics by 6.4% during the third quarter. JPMorgan Chase & Co. now owns 421,494 shares of the biotechnology company’s stock worth $3,199,000 after purchasing an additional 25,287 shares in the last quarter. 78.51% of the stock is owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Featured Article: Derivative

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply